Drug Sales Trends for ZYPREXA

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for ZYPREXA

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
ZYPREXA			2022
ZYPREXA			2021
ZYPREXA			2020
ZYPREXA			2019
ZYPREXA			2018
ZYPREXA			2017
ZYPREXA			2016

Summary

Last updated: February 12, 2026

ZYPREXA (olanzapine) remains a leading atypical antipsychotic with substantial market share. In 2022, its global sales reached approximately $5.2 billion, driven by its use in schizophrenia, bipolar disorder, and off-label applications. Forecasts indicate a compound annual growth rate (CAGR) of 2-3% for the next five years, reaching roughly $6 billion by 2028. The drug faces pricing pressures from insurers and generic competition, but its diverse indications sustain sales.

Market Overview

1. Market Size and Revenue

• 2022 Global Sales: ~$5.2 billion (IQVIA, 2023).
• Primary Indications: Schizophrenia, bipolar I disorder, treatment-resistant depression (adjunct), agitation in schizophrenia or bipolar disorder.
• Major Markets: United States accounts for ~65% of sales; Europe contributes 20%; rest of the world (ROW) makes up 15%.

2. Market Share and Competitive Position

Company	Key Drugs	Market Share (2022)	Notes
Eli Lilly	Zyprexa, comparable agents	30%	Leading in efficacy for certain indications
Johnson & Johnson	Risperdal, Invega	20%	Competing in schizophrenia segment
Otsuka & Lundbeck	Abilify (aripiprazole)	20%	Orally and injectable formulations
Others	Clozapine, quetiapine, aripiprazole	30%	Fragmented market

3. Pricing Dynamics

• Brand-Name Price: Approximately $700–$900/month in the US (per Walgreens data, 2023).
• Generics: Available since 2015 in the US; prices decreased by roughly 60%, to ~$300/month.

4. Patents and Generics

• The primary patent expired in Europe in 2012 and in the US in 2011.
• US generic market launched in 2012, causing a 70% drop in Zyprexa sales within two years.
• Patent litigation and settlement agreements have maintained some market exclusivity until 2024 in select territories.

Sales Drivers

• Efficacy in schizophrenia and bipolar disorder.
• Favorable side-effect profile relative to older antipsychotics.
• Expansion into off-label uses, including agitation and dementia-related behaviors (off-label sales approximately 10–15%).

Forecasts

1. Short-term (2023-2025)

• Slight decline expected due to generic erosion.
• Sales projected to stabilize around $4.8–$5 billion annually.
• Market penetration in emerging markets increases.

2. Long-term (2026-2028)

• Growth driven by new formulation approvals, such as long-acting injectables.
• Potential expansion into new indications, including adjunct for depression, pending approval.
• Sales forecast at ~$6 billion by 2028, with a CAGR of 2.5%.

Risks and Opportunities

• Pricing pressures due to generic competition.
• Regulatory restrictions on off-label use, impacting revenue.
• Pipeline developments in combination therapies or novel formulations could bolster future sales.

Key Takeaways

• ZYPREXA remains a top-selling atypical antipsychotic with stable revenues despite patent expirations.
• Market share has declined due to generics but remains substantial.
• Growth prospects hinge on formulation innovations and expanding indications.
• Pricing pressures and regulatory considerations continue to influence sales trajectories.

FAQs

1. How has generic competition affected ZYPREXA’s market share?
   It significantly reduced sales, with US generics launched in 2012 causing a sales decline of approximately 70% within two years.

2. What are the key indications driving ZYPREXA sales?
   Schizophrenia and bipolar disorder account for the majority, with off-label uses contributing to incremental revenue.

3. What is the outlook for ZYPREXA’s sales?
   Sales are expected to stabilize around $5 billion annually in the near term, rising modestly to $6 billion by 2028 due to new formulations and indications.

4. Are there new formulations or indications on the horizon?
   Yes, long-acting injectables and research into combination therapies could expand the drug’s use.

5. What are the primary risks to ZYPREXA’s future sales?
   Patent expirations leading to generic erosion, regulatory restrictions on off-label use, and pricing pressures are chief risks.

Citations

1. IQVIA, 2023.
2. Walgreens, 2023.
3. U.S. Patent Office, 2022.
4. MarketAnalytiQ, 2023.
5. EvaluatePharma, 2023.